Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Jul;85(1):e10-e12.
doi: 10.1016/j.jinf.2022.04.027. Epub 2022 Apr 21.

Lack of efficacy for sotrovimab use in patients with COVID-19: A meta-analysis

Guangyu Ao  1 , Toni Li  2 , Yushu Wang  3 , Carolyn Tran  4 , Xin Qi  5
Affiliations
Meta-Analysis

Lack of efficacy for sotrovimab use in patients with COVID-19: A meta-analysis

Guangyu Ao et al. J Infect. 2022 Jul.
No abstract available

Keywords: COVID-19; Mortality; SARS-CoV-2; Sotrovimab.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare that they have no competing interest.

Figures

Fig. 1
Fig. 1
A Association between sotrovimab treatment and mortality. Figure 1B Association between sotrovimab treatment and developing severe COVID-19.
See this image and copyright information in PMC

References

    1. Luo L., Luo T., Du M., Mei H., Hu Y. Efficacy and safety of tocilizumab in hospitalized COVID-19 patients: a systematic review and meta-analysis. J Infect. 2022;84(3):418–467. - PMC - PubMed
    1. Heo Y.A. Sotrovimab: First Approval. Drugs. 2022;82(4):477–484. - PMC - PubMed
    1. Hoffmann M., Krüger N., Schulz S., et al. The Omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic. Cell. 2022;185(3) 447-456.e11. - PMC - PubMed
    1. Gupta A., Gonzalez-Rojas Y., Juarez E., et al. Effect of sotrovimab on hospitalization or death among high-risk patients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2022;327(13):1236–1246. - PMC - PubMed
    1. Huang D.T., McCreary E.K., Bariola J.R., et al. Effectiveness of casirivimab and imdevimab, and sotrovimab during Delta variant surge: a prospective cohort study and comparative effectiveness randomized trial. medRxiv 2021:2021.12.23.21268244. doi: 10.1101/2021.12.23.21268244. - DOI - PMC - PubMed